APPLY

2026

Winner of the €100,000 Jorge Ruas Award

SafeAlleleSCA is the winner of the Tecnimede Open Innovation Competition 2026.

Developed by a team from GeneT – Gene Therapy Center of Excellence at the University of Coimbra, SafeAlleleSCA is a first-in-class gene therapy platform designed to selectively silence the disease-causing genetic variant while preserving normal gene function.

Its lead programme targets Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado–Joseph disease, a rare, inherited and progressive neurodegenerative disorder that leads to a gradual loss of coordination, balance and muscle control.

SafeAlleleSCA aims to advance a precision gene therapy approach for SCA3 by targeting the genetic cause of the disease while preserving normal gene function.

Preclinical studies have shown strong efficacy in mouse models and broad distribution of the therapy across relevant areas of the central nervous system in non-human primates.

Selected from the 10 finalist projects presented at the Tecnimede Open Innovation Competition 2026 Final Event, SafeAlleleSCA received the Jorge Ruas Award.

Team:
Ana Carolina Silva
Diogo Magalhães e Silva
Laetitia Gaspar
Luís Pereira de Almeida
Rui Jorge Nobre

Organisation:
GeneT-Gene Therapy Center of Excellence, University of Coimbra